Abstracts tagged "Hydroxychloroquine"

Abstract Number: 2107 • 2015 ACR/ARHP Annual Meeting
Initiation of Combination Triple Therapy in Real World Clinical Practice Rarely Replicates the Protocols Used in Randomized Controlled Trials.
Grant W. Cannon¹, Chia-Chen Teng², Ted R. Mikuls³, Jeffrey R. Curtis⁴, Derek Tang⁵, Bradley S. Stolshek⁵ and Brian Sauer⁶, ¹Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, ³Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Amgen, Inc., Thousand Oaks, CA, ⁶Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT
Background/Purpose: Combination therapy with methotrexate (MTX), sulfasalazine (SUL), and hydroxychloroquine (HCQ) [triple therapy] is an effective treatment for rheumatoid arthritis (RA). Randomized controlled trials…
Abstract Number: 484 • 2015 ACR/ARHP Annual Meeting
Race Plays a Role in Influencing the Modest Lipid Lowering Effects of Hydroxychloroquine in Patients with Rheumatoid Arthritis, Independent of Statin Use
Myriam Guevara¹, Bernard NG¹ and Nancy Gove², ¹Rheumatology, University of Washington, Seattle, WA, ²Biostatistics, Seattle Children's, Seattle, WA
Background/Purpose: Despite remarkable improvements in RA treatment, there is evidence indicating that the mortality gap between RA patients and the general population is not closing.…
Abstract Number: 425 • 2015 ACR/ARHP Annual Meeting
Impact of in Utero Hydroxychloroquine Exposure on Age of Onset of Cutaneous Neonatal Lupus
Julie Barsalou¹, Nathalie Costedoat-Chalumeau², Cesar Fors-Nieves³, Ummara Shah⁴, Patrick Brown⁵, Carl Laskin⁶, Nathalie Morel², Kateri Levesque⁷, Jill P. Buyon⁸, Earl Silverman⁹ and Peter M. Izmirly¹⁰, ¹Pediatric Rheumatology, CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada, ²Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ³Division of Rheumatology, NYU School of Medicine, New York, NY, ⁴Medicine, Strong Memorial Hospital, University of Rochester, Rochester, NY, ⁵University of Toronto, Toronto, ON, Canada, ⁶Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁷Internal Medicine, CHU Ste-Justine, Montréal, QC, Canada, ⁸NYU School of Medicine, New York, NY, ⁹Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ¹⁰Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Biopsy specimens of cutaneous neonatal lupus (cNL) lesions usually show interface dermatitis. Hydroxychloroquine (HCQ) is an effective treatment for interface dermatitis seen in connective…
Abstract Number: 2374 • 2014 ACR/ARHP Annual Meeting
Use of Hydroxychloroquine Associated with Improved Lipid Profile in Rheumatoid Arthritis Patients
Jose Felix Restrepo¹, Inmaculada del Rincon², Emily Molina³, Daniel Battafarano⁴ and Agustin Escalante⁵, ¹Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Medicine/Clinical Immunology, UTHSCSA, San Antonio, TX, ³Rheumatology, University of Texas Health Science Center, San Antonio, TX, ⁴Rheumatology, San Antonio Military Medical Center, JBSA - Ft Sam Houston, TX, ⁵Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX
Background/Purpose: Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality in rheumatoid arthritis (RA). CVD risk factor reduction, such as reducing…
Abstract Number: 1846 • 2014 ACR/ARHP Annual Meeting
The Association Between Hydroxychloroquine Treatment and Cardiovascular Morbidity Among Rheumatoid Arthritis Patients
Michael Shapiro¹ and Yair Levy², ¹Haim Lebanon 55, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Internal Medicine E, Meir Medical Center, Kfar Saba, Israel
Background/Purpose: Accelerated atherosclerosis and cardiovascular disease are the main causes of mortality in Rheumatoid Arthritis (RA). The anti-malarial drug Hydroxychloroquine (HCQ) has long been used…
Abstract Number: 1614 • 2013 ACR/ARHP Annual Meeting
Hydroxychloroquine Reverse The Elevation Of Interferon-Alfa Initiated By TLR-9 Agonist Which Irresponsive To Glucocorticoid
Ou Jin¹, Xi Zhang¹, Lingkai Fang¹, Qiuxia Li¹, Hongyue Huang¹, Zhiming Lin², Zetao Liao¹, Dongfang Lin¹, Chengcheng Hou¹ and Jieruo Gu³, ¹Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, ²Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ³Medicine, Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by chronic stimulation of the innate immune system by endogenous nucleic acids through toll-like receptors (TLRs) pathway, which…
Abstract Number: 606 • 2013 ACR/ARHP Annual Meeting
Characteristics Of Lupus Nephritis: Data From a Large Multicenter Registry Of Patients With Systemic Lupus Erythematosus
Diane L. Kamen¹, Graciela S. Alarcon², Jill P. Buyon³, Mary Anne Dooley⁴, Richard A. Furie⁵, David S. Pisetsky⁶ and Tammy O. Utset⁷, ¹Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ²Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁵The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, ⁶Department of Medicine, Duke University Medical Center, Durham, NC, ⁷Rheumatology, University of Chicago Medical Center, Chicago, IL
Background/Purpose: Renal disease is strongly associated with morbidity and mortality among SLE patients. We utilized the Lupus Clinical Trials Consortium, Inc. longitudinal registry of SLE…
Abstract Number: 635 • 2012 ACR/ARHP Annual Meeting
Elevated Transglutaminase Levels On Microparticles From Systemic Lupus Erythematosus Patients
Leslie Harris¹, Ratnesh Chopra¹, Ann K. Rosenthal² and Mary E. Cronin³, ¹Division of Rheumatology/Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, ²Div of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ³Rheumatology, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Systemic Lupus Erythematosus ( SLE) is characterized by the formation of autoantibodies, and over-exuberant antigen presentation may account for some of this pathology .…
Abstract Number: 1933 • 2012 ACR/ARHP Annual Meeting
Incidence and Early Detection of Retinal Toxicity in Patients Treated with Chloroquine and Hydroxichloroquine in Rheumatology Practice
Sandra Soro Marin¹, Ana del Carmen Haro Martínez¹, Deseada Palma Sanchez¹, María del Rocío Gonzalez Molina¹, Marta Mayor Gonzalez² and Elena Rubio Velazquez³, ¹Rheumatology, Rafael Mendez Hospital, Spain., Lorca (Murcia), Spain, ²Rheumatology, Rafael Mendez Hospital, Lorca (Murcia), Spain, ³Ophthalmology, Rafael Mendez Hospital, Lorca (Murcia)
Background/Purpose: The antimalarial drugs are considered safe and well tolerated, with low risk of side effects. Hydroxychloroquine is considered safer but less effective than chloroquine,…
Abstract Number: 2482 • 2012 ACR/ARHP Annual Meeting
Hydroxychloroquine Has Lipid-Lowering Effects in US Veterans with Rheumatoid Arthritis
Nicole A. Kieffer¹, Gail S. Kerr², J. Steuart Richards³, Lisa A. Davis⁴, Liron Caplan⁵, Jeffrey Huang⁶, Grant W. Cannon⁷, Harlan Sayles⁸ and Kaleb Michaud⁹, ¹Division of Rheumatology, Georgetown University, Washington, DC, ²Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ³Rheumatology, Washington DC VA and Georgetown University, Washington, DC, ⁴Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, ⁵Div of Rheumatology, Denver VA and Univ of Colorado School of Medicine, Aurora, CO, ⁶Rheumatology, Washington DC VA and Howard University Hospital, Washington, DC, ⁷Division of Rheumatology, George E. Wahlen VA Medical Center, Salt Lake City, UT, ⁸Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁹Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Recent data report significant decreases in low-density lipoprotein (LDL) and total cholesterol (TC) levels in predominantly female Caucasian rheumatoid arthritis (RA) patients treated with…
Abstract Number: 2569 • 2012 ACR/ARHP Annual Meeting
Hydroxychloroquine Reduces Thrombosis in Systemic Lupus Erythematosus, Particularly in Antiphospholipid Positive Patients
Genevieve Law¹, Laurence S. Magder², Hong Fang³ and Michelle Petri³, ¹Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada, ²Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Past studies, mostly cross-sectional, have found a reduction in thrombosis in systemic lupus erythematosus (SLE) patients taking hydroxychloroquine (HCQ). We examined the relationship between…